Suppr超能文献

相似文献

1
The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.
Int J Mol Sci. 2017 Jun 27;18(7):1374. doi: 10.3390/ijms18071374.
3
Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy.
Curr Drug Targets. 2015;16(13):1448-63. doi: 10.2174/1389450115666140528151649.
4
[Lung cancer : What has been confirmed in therapy?].
Internist (Berl). 2017 Dec;58(12):1258-1263. doi: 10.1007/s00108-017-0339-4.
6
[Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Klin Onkol. 2016 Fall;29 Suppl 4(Suppl 4):78-87.
7
The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience.
Crit Rev Oncol Hematol. 2015 Nov;96(2):319-27. doi: 10.1016/j.critrevonc.2015.05.020. Epub 2015 Jun 7.
8
Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?
Cancer Metastasis Rev. 2015 Mar;34(1):129-44. doi: 10.1007/s10555-015-9550-8.
9
Immunotherapy for lung cancer: for whom the bell tolls?
Tumour Biol. 2015 Mar;36(3):1411-22. doi: 10.1007/s13277-015-3285-6. Epub 2015 Mar 4.
10
Evolving Treatment Options for Lung Cancer.
Hematol Oncol Clin North Am. 2017 Feb;31(1):xiii-xiv. doi: 10.1016/j.hoc.2016.09.001.

引用本文的文献

1
Characterization of the immune cell infiltration patterns in lung adenocarcinoma to facilitate immunotherapy.
Heliyon. 2025 Feb 15;11(4):e42720. doi: 10.1016/j.heliyon.2025.e42720. eCollection 2025 Feb 28.
3
Does needle gauge affect complication rates of computed tomography-guided lung biopsy?
J Thorac Dis. 2024 Jul 30;16(7):4310-4318. doi: 10.21037/jtd-24-240. Epub 2024 Jul 16.
4
The Effect of MiR320a on Lung Cancer.
Microrna. 2024;13(3):167-174. doi: 10.2174/0122115366296148240530072346.
6
Investigating the role of let-7a microRNA in cisplatin sensitivity of A549 lung cancer cells.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):3979-3984. doi: 10.1007/s00210-023-02858-y. Epub 2023 Nov 22.
9
Genistein-induced mitochondrial dysfunction and FOXO3a/PUMA expression in non-small lung cancer cells.
Pharm Biol. 2022 Dec;60(1):1876-1883. doi: 10.1080/13880209.2022.2123933.

本文引用的文献

2
T cell exhaustion: from pathophysiological basics to tumor immunotherapy.
Cell Commun Signal. 2017 Jan 5;15(1):1. doi: 10.1186/s12964-016-0160-z.
3
Cancer Statistics, 2017.
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
6
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.
8
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
9
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Lung Cancer. 2017 May;107:41-49. doi: 10.1016/j.lungcan.2016.06.015. Epub 2016 Jun 17.
10
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Front Oncol. 2016 May 4;6:112. doi: 10.3389/fonc.2016.00112. eCollection 2016.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验